Uridine triacetate is an oral acetylated pro-drug of uridine that is deacetylated in the body to yield uridine in the circulation. Uridine competes with the fluorouracil metabolite FUTP for incorporation into RNA and thereby reduces fluorouracil cytotoxicity. It is studied in mitochondrial diseases.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Vistogard, Xuriden, RG-2133, PN-401
Drug type
Small molecule
Pathways
pyrimidine nucleotide metabolism, RNA incorporation of fluorouracil metabolite (FUTP), thymidylate synthase-mediated DNA synthesis
From the indications section of the FDA label (version of Mar 31, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.